Menu Search
Equities

Celldex Therapeutics Inc

CLDX:NAQ

Celldex Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)41.14
  • Today's Change-0.71 / -1.70%
  • Shares traded1.21m
  • 1 Year change+54.60%
  • Beta1.5703
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy5
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Celldex Therapeutics, Inc. have a median target of 68.00, with a high estimate of 90.00 and a low estimate of 37.00. The median estimate represents a 65.21% increase from the last price of 41.16.
High118.7%90.00
Med65.2%68.00
Low-10.1%37.00

Earnings history & estimates in USD

On Aug 08, 2024, Celldex Therapeutics, Inc. reported 2nd quarter 2024 losses of -0.540 per share. This result exceeded the -0.590 consensus loss of the 9 analysts covering the company and exceeded last year's 2nd quarter results by 16.92%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate+2.25%
Celldex Therapeutics, Inc. reported annual 2023 losses of -2.92 per share on Feb 26, 2024.
Average growth rate-1.69%
More ▼

Revenue history & estimates in USD

of 156.00k. This missed the 916.00k consensus estimate of the 4 analysts following the company.
Average growth rate+117.48%
Celldex Therapeutics, Inc. had revenues for the full year 2023 of 6.88m. This was 192.02% above the prior year's results.
Average growth rate+53.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.